A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, providing durable and even curative responses. However, most patients do not respond and current biomarkers (eg, programmed death 1 ligand 1 [PD-L1]), mismatch repair deficiency [dMMR]/high microsatellite i...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2026-01-01
|
| Serier: | Journal of Translational Medicine |
| Online adgang: | https://doi.org/10.1186/s12967-025-07378-2 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
